What are the side effects of teicoplanin?

Teicoplanin Side Effects

Teicoplanin is generally well-tolerated with significantly fewer adverse effects compared to vancomycin, particularly causing minimal nephrotoxicity and rare anaphylactoid reactions. 1

Common Side Effects

The most frequently reported adverse reactions with teicoplanin include:

• Local reactions at injection site - most common with intramuscular administration
• Hypersensitivity reactions: itching, urticaria, rash, and drug fever 2, 1
• Gastrointestinal upset 2

Serious but Rare Adverse Effects

Hematologic Toxicity

• Pancytopenia - documented with excessive dosing (case report with 400 mg every 12 hours) 3
• Neutropenia, eosinophilia, and thrombocytopenia have been reported 4

Neurologic Effects

• Tingling of extremities and tongue
• Slurred speech, dizziness, vertigo
• Paresthesia and seizures 2

Renal Toxicity

• Nephrotoxicity is significantly less common than with vancomycin 1
• Elevated BUN and creatinine, decreased creatinine clearance 2
• Decreased urine output 2

Respiratory

• Respiratory distress and apnea 2

Anaphylaxis

• Anaphylactoid reactions ("red man syndrome") are seldom observed, unlike vancomycin 1

Cross-Reactivity with Vancomycin

Patients with prior vancomycin-associated adverse reactions have a significantly higher risk of teicoplanin reactions (23.1% vs 5.3%) 5. Key risk factors include:

• History of drug allergy
• Multiple organ involvement in vancomycin hypersensitivity reactions
• Clinicians must exercise caution when switching from vancomycin to teicoplanin in patients with prior vancomycin hypersensitivity 5

Dose-Related Considerations

Higher maintenance doses (10-12 mg/kg daily) do not increase toxicity rates despite achieving higher therapeutic levels 4, 6. A study of 549 patients showed:

• No increased frequency of potentially toxic levels (>60 mg/L) with 600 mg vs 400 mg daily dosing
• No difference in incidence of neutropenia, eosinophilia, thrombocytopenia, or acute renal injury between dose groups 4

Clinical Monitoring Recommendations

While routine therapeutic drug monitoring is not required by the manufacturer 7, serum level monitoring should be considered in:

• S. aureus endocarditis or septic arthritis (target trough ≥20 mg/L)
• Patients with major burns
• Intravenous drug users
• Rapidly changing renal function 7

Key Clinical Advantages Over Vancomycin

Teicoplanin demonstrates a superior safety profile with:

• Lower nephrotoxicity, especially when combined with aminoglycosides 1
• Minimal anaphylactoid reactions 1
• Better tolerability allowing once-daily dosing 1, 8
• No requirement for regular serum level monitoring in most patients 8